Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.45 |
| ▸ | MTOR | P42345 | 9/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30308905 | 1.00 | PIK3CA (0.45) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL25227992 | 0.92 | PIK3CA (0.48) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL25278157 | 0.89 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL27271080 | 0.87 | PIK3CA (0.41) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL30308875 | 0.87 | PIK3CA (0.41) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL25227750 | 0.83 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL25277713 | 0.82 | PIK3CA (0.45) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL25725271 | 0.82 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL30308893 | 0.81 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL27271089 | 0.81 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | PIK3CA 3369/4885PIK3CD 3769/4885PIK3CG 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.